Bringing Hope To Cancer Patients

Our Mission

Our mission is to give patients hope and assist oncologists make treatment decisions by providing personalized chemotherapy regimens that increase patient survival while lowering healthcare costs. We use our proprietary anticancer drug screening capabilities to evaluate the efficacy of current standard-of-care treatments, to guide therapy, and positively empower all cancer patients.

ChemoID Assay Rationale

ChemoID testing begins with a small tumor sample biopsy that is sent to our lab where the cancer cells are grown for testing. The process involves growing bulk tumor cells and enrichment of cancer stem cells from individual patient biopsies or recovered from fluid specimens. Those cells then are treated with various standard of care FDA approved chemotherapeutic agents selected by the patient’s oncologist to determine how many tumor-derived cells and CSCs are killed using each drug or combinations. A response curve is generated for each drug evaluated, and the data are presented graphically as the cytotoxic index for the oncologist.

​ChemoID enables faster reaction time to discover and administer the optimum selection of chemotherapy drug(s), increasing patient survival, lowering treatment costs by eliminating unnecessary chemotherapies, and decreasing toxicity side effects. The cost of cancer patient care with accurately defined chemotherapy can be substantially reduced.

ChemoID personalized chemotherapy assay enables each patient to avoid the severe toxicity caused by administering non-effective and unnecessary multiple chemotherapeutic drugs without lab-measured comparisons to validate their efficacy for eradicating that patient’s specific cancer.

ChemoID Assay allows various currently available FDA approved standard-of-care chemotherapy drugs to be tested for efficacy against CSCs as well as the bulk of tumor cells. This process identifies the most effective combination of chemotherapy drugs to defeat a patient’s cancer, resulting in reduced toxicity to the patient, minimizing the overall cost of treatment, and increasing survivability.

ChemoID test results are reported to the oncologist in 14 days for surgical and fluid biopsy specimens and 20 days for core biopsies, to positively impact patient outcomes.

The market demand for a patient-centric approach to manage costs and enhance patient treatment outcomes in a timely and useful manner is precisely the evolution in Personalized Cancer Treatment that ChemoID is uniquely enabled to provide.